|
|
Article: 'Proventil Repetabs,' Schering-Plough's new asthma product, is approved for marketing in United States.
- Article from:
- PR Newswire
- Article date:
- July 14, 1987
CopyrightCOPYRIGHT 1987 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
'PROVENTIL REPETABS,' SCHERING-PLOUGH'S NEW ASTHMA PRODUCT,
IS APPROVED FOR MARKETING IN UNITED STATESPRODUCT,
MADISON, N.J., July 14 /PRNewswire/ -- 'Proventil Repetabs,' Schering-Plough Corporation's (NYSE: SGP) new, long-acting asthma medication, has been approved for marketing in the United States by the U.S. Food and Drug Administration and will be introduced in August.
A prescription product from Schering Laboratories, 'Proventil Repetabs' is the first and only beta agonist bronchodilator to be marketed in the United States for twice-a-day use. The new tablets are indicated for relief of symptoms associated with asthma, ...